Table 2. Analyses of pathways implicated by schizophrenia genome-wide studies.
| Pathway | DE genes (q<0.1) |
24 h |
48 h |
||
|---|---|---|---|---|---|
| P | OR (95% CI) | P | OR (95% CI) | ||
| Synaptic genes | All | 0.90 | 0.94 (0.57–1.56) | 2.8 × 10−7 | 2.13 (1.63–2.78) |
| (1043 genes) | Downregulated | 0.86 | 0.85 (0.41–1.74) | 1.0 | 0.95 (0.5–1.81) |
| Upregulated | 0.70 | 1.11 (0.54–2.28) | 3.2 × 10−8 | 2.54 (1.88–3.44) | |
| Postsynaptic | All | 0.78 | 0.88 (0.49–1.58) | 0.06 | 1.4 (0.99–1.99) |
| density | Downregulated | 1.0 | 0.86 (0.38–1.97) | 0.39 | 0.63 (0.28–1.44) |
| (1457 genes) | Upregulated | 1.0 | 0.98 (0.43–2.24) | 0.0049 | 1.82 (1.23–2.71) |
| ARC | All | 1.0 | N/A | 0.0096 | 5.51 (1.86–16.32) |
| (28 genes) | Downregulated | 1.0 | N/A | 0.20 | 4.96 (0.61–40.5) |
| Upregulated | 1.0 | N/A | 0.03 | 5.03 (1.4–18.09) | |
| NMDA receptor | All | 1.0 | 0.89 (0.12–6.45) | 0.17 | 1.94 (0.7–5.38) |
| (61 genes) | Downregulated | 1.0 | N/A | 0.24 | 2.24 (0.53–9.43) |
| Upregulated | 0.41 | 1.94 (0.26–14.27) | 0.32 | 1.84 (0.43–7.88) | |
| FMRP interactors | All | 0.08 | 1.49 (0.96–2.32) | 4.7 × 10−5 | 1.92 (1.43–2.57) |
| (842 genes) | Downregulated | 0.07 | 1.61 (0.98–2.65) | 0.71 | 1.13 (0.57–2.21) |
| Upregulated | 1.0 | 0.84 (0.31–2.28) | 1.5 × 10−4 | 1.98 (1.42–2.75) | |
| Calcium channel | All | 1.0 | N/A | 0.0056 | 6.61 (2.19–19.97) |
| subunits | Downregulated | 1.0 | N/A | 1.0 | N/A |
| (26 genes) | Upregulated | 1.0 | N/A | 0.0098 | 5.68 (1.84–17.52) |
| Cav2 interactors | All | 0.08 | N/A | 0.11 | 1.68 (0.9–3.1) |
| (207 genes) | Downregulated | 0.27 | N/A | 0.73 | 0.47 (0.06–3.36) |
| Upregulated | 0.65 | N/A | 0.04 | 2.09 (1.08–4.05) | |
Abbreviations: ARC, neuronal activity-regulated cytoskeleton-associated protein postsynaptic signaling complexes; Cav2, voltage-gated calcium channel; CI, confidence interval; DE, differentially expressed; FMRP, fragile X mental retardation protein; NMDA, N-methyl-D-aspartate; OR, odds ratio. Boldface shows P<0.01.